Phlexglobal, a technology and services provider for the life sciences industry, announced the general availability of the industry’s first and only complete TMF management offering from a single expert provider. The company’s new PhlexTMF+ provides a one-stop, full-service solution that encompasses all the software and services required for effective TMF management and ongoing inspection-readiness. Organizations can be confident that their Trial Master File is being managed by experts every step of the way, from planning and document processing and study closeout.
With PhlexTMF+, life sciences organizations now have ready access to the latest advances in eTMF SaaS software, the world’s leading TMF experts, and best practices-based processes proven to optimize TMF quality, completeness, and timeliness – from a single provider and in one seamless offering. Companies gain ongoing TMF compliance, as well as the freedom to shift study resources from time-consuming TMF management to other critical objectives, reducing the risk of inspection findings and submission delays.
“You can think of PhlexTMF+ as ‘TMF management as a service,’” observes Karen Roy, Phlexglobal’s Chief Strategy Officer and Chair, TMF Reference Model. “By delivering everything critical to Trial Master File health, including purpose-built SaaS eTMF software, workflows, and expert guidance, we remove the burden of TMF compliance from our customers.”
Building on Phlexglobal’s decades of industry leadership in Trial Master File technology and best practices, the innovative new solution standardizes end-to-end TMF management to ensure consistent, accurate, and current compliance throughout the TMF lifecycle. What’s more, PhlexTMF+ fits each organization’s unique requirements, providing agile, fit-for-purpose TMF management – eliminating paying for software and services that don’t support TMF health.
Key benefits of PhlexTMF+ include:
“PhlexTMF+ is further evidence of Phlexglobal’s authoritative position helping life sciences companies worldwide stay compliant with ever-shifting regulatory mandates,” said John McNeill, Chief Executive Officer of Phlexglobal. “We’ve transformed a traditionally siloed and challenging TMF management process into a seamless, expert solution from a single source, providing our customers with even greater compliance peace of mind.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.